BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 27185872)

  • 1. IGF2 and IGF1R in pediatric adrenocortical tumors: roles in metastasis and steroidogenesis.
    Peixoto Lira RC; Fedatto PF; Marco Antonio DS; Leal LF; Martinelli CE; de Castro M; Tucci S; Neder L; Ramalho L; Seidinger AL; Cardinalli I; Mastellaro MJ; Yunes JA; Brandalise SR; Tone LG; Rauber Antonini SR; Scrideli CA
    Endocr Relat Cancer; 2016 Jun; 23(6):481-93. PubMed ID: 27185872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cytoskeleton actin binding protein filamin A impairs both IGF2 mitogenic effects and the efficacy of IGF1R inhibitors in adrenocortical cancer cells.
    Catalano R; Giardino E; Treppiedi D; Mangili F; Morelli V; Elli FM; Serban AL; Luconi M; Mannelli M; Spada A; Arosio M; Mantovani G; Peverelli E
    Cancer Lett; 2021 Jan; 497():77-88. PubMed ID: 33075426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer.
    De Martino MC; van Koetsveld PM; Feelders RA; de Herder WW; Dogan F; Janssen JAMJL; Hofste Op Bruinink D; Pivonello C; Waaijers AM; Colao A; de Krijger RR; Pivonello R; Hofland LJ
    Endocrine; 2019 Jun; 64(3):673-684. PubMed ID: 30838516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pediatric adrenocortical tumors: molecular events leading to insulin-like growth factor II gene overexpression.
    Wilkin F; Gagné N; Paquette J; Oligny LL; Deal C
    J Clin Endocrinol Metab; 2000 May; 85(5):2048-56. PubMed ID: 10843195
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Panebianco F; Kelly LM; Liu P; Zhong S; Dacic S; Wang X; Singhi AD; Dhir R; Chiosea SI; Kuan SF; Bhargava R; Dabbs D; Trivedi S; Gandhi M; Diaz R; Wald AI; Carty SE; Ferris RL; Lee AV; Nikiforova MN; Nikiforov YE
    Proc Natl Acad Sci U S A; 2017 Feb; 114(9):2307-2312. PubMed ID: 28193878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-Like Growth Factor and SLC12A7 Dysregulation: A Novel Signaling Hallmark of Non-Functional Adrenocortical Carcinoma.
    Brown TC; Nicolson NG; Stenman A; Juhlin CC; Gibson CE; Callender GG; Korah R; Carling T
    J Am Coll Surg; 2019 Sep; 229(3):305-315. PubMed ID: 31034883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor system on adrenocortical tumorigenesis.
    Ribeiro TC; Latronico AC
    Mol Cell Endocrinol; 2012 Mar; 351(1):96-100. PubMed ID: 22019903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
    Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
    Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors.
    Almeida MQ; Fragoso MC; Lotfi CF; Santos MG; Nishi MY; Costa MH; Lerario AM; Maciel CC; Mattos GE; Jorge AA; Mendonca BB; Latronico AC
    J Clin Endocrinol Metab; 2008 Sep; 93(9):3524-31. PubMed ID: 18611974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IGF2 role in adrenocortical carcinoma biology.
    Pereira SS; Monteiro MP; Costa MM; Moreira Â; Alves MG; Oliveira PF; Jarak I; Pignatelli D
    Endocrine; 2019 Nov; 66(2):326-337. PubMed ID: 31378849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined steroidogenic characters of fetal adrenal and Leydig cells in childhood adrenocortical carcinoma.
    Fujisawa Y; Sakaguchi K; Ono H; Yamaguchi R; Kato F; Kagami M; Fukami M; Ogata T
    J Steroid Biochem Mol Biol; 2016 May; 159():86-93. PubMed ID: 26940356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation of N-cadherin/β-catenin expression in adrenocortical tumors.
    Rubin B; Regazzo D; Redaelli M; Mucignat C; Citton M; Iacobone M; Scaroni C; Betterle C; Mantero F; Fassina A; Pezzani R; Boscaro M
    Tumour Biol; 2016 Oct; 37(10):13545-13555. PubMed ID: 27468715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults.
    Faria AM; Almeida MQ
    Mol Cell Endocrinol; 2012 Mar; 351(1):52-7. PubMed ID: 22019901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sonic hedgehog signaling is active in human adrenal cortex development and deregulated in adrenocortical tumors.
    Gomes DC; Leal LF; Mermejo LM; Scrideli CA; Martinelli CE; Fragoso MC; Latronico AC; Tone LG; Tucci S; Yunes JA; Cardinalli IA; Mastellaro MJ; Brandalise SR; Ramalho F; Moreira AC; Ramalho LN; de Castro M; Antonini SR
    J Clin Endocrinol Metab; 2014 Jul; 99(7):E1209-16. PubMed ID: 24712566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.
    Xu L; Qi Y; Xu Y; Lian J; Wang X; Ning G; Wang W; Zhu Y
    Oncotarget; 2016 Jun; 7(24):36235-36246. PubMed ID: 27105537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.
    Altieri B; Sbiera S; Della Casa S; Weigand I; Wild V; Steinhauer S; Fadda G; Kocot A; Bekteshi M; Mambretti EM; Rosenwald A; Pontecorvi A; Fassnacht M; Ronchi CL
    Oncotarget; 2017 Feb; 8(6):9323-9338. PubMed ID: 28030838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone morphogenetic proteins 2 and 5 are down-regulated in adrenocortical carcinoma and modulate adrenal cell proliferation and steroidogenesis.
    Johnsen IK; Kappler R; Auernhammer CJ; Beuschlein F
    Cancer Res; 2009 Jul; 69(14):5784-92. PubMed ID: 19584291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IGF2 promotes growth of adrenocortical carcinoma cells, but its overexpression does not modify phenotypic and molecular features of adrenocortical carcinoma.
    Guillaud-Bataille M; Ragazzon B; de Reyniès A; Chevalier C; Francillard I; Barreau O; Steunou V; Guillemot J; Tissier F; Rizk-Rabin M; René-Corail F; Al Ghuzlan A; Assié G; Bertagna X; Baudin E; Le Bouc Y; Bertherat J; Clauser E
    PLoS One; 2014; 9(8):e103744. PubMed ID: 25089899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy.
    Sanderson MP; Hofmann MH; Garin-Chesa P; Schweifer N; Wernitznig A; Fischer S; Jeschko A; Meyer R; Moll J; Pecina T; Arnhof H; Weyer-Czernilofsky U; Zahn SK; Adolf GR; Kraut N
    Mol Cancer Ther; 2017 Oct; 16(10):2223-2233. PubMed ID: 28729397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis.
    Nakamura Y; Yamazaki Y; Felizola SJ; Ise K; Morimoto R; Satoh F; Arai Y; Sasano H
    Endocrinol Metab Clin North Am; 2015 Jun; 44(2):399-410. PubMed ID: 26038208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.